Clinical, virological and immunological responses in danish hiv patients receiving raltegravir as part of a salvage regimen

Clinical Epidemiology

Volumn 2, Issue 1, 2010, Pages 145-151

  Engsig, Frederik N ^a   Gerstoft, Jan ^a   Kronborg, Gitte ^b   Larsen, Carsten S ^c   Pedersen, Gitte ^d   Audelin, Anne M ^e   Jørgensen, Louise B ^e   Obel, Niels ^a  

^a Rigshospitalet   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e STATENS SERUM INSTITUT   (Denmark)

Author keywords

Efficacy; HIV; Matched cohort; Raltegravir; Salvage regime

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; MULTIDRUG RESISTANCE; POPULATION RESEARCH; RISK ASSESSMENT; SALVAGE THERAPY; VIRUS LOAD;

EID: 77955343181     PISSN: None     EISSN: 11791349     Source Type: Book Series    
DOI: 10.2147/clep.s10478     Document Type: Article

References (24)

1. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146(2):87-95.
2. Engsig FN, Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Obel N. Inpatient admissions and outpatient visits in persons with and without HIV infection in Denmark, 1995-2007. AIDS. 2010;24(3):457-461.
3. Lohse N, Obel N, Kronborg G, et al. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. AIDS. 2005;19(8):815-822.
4. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescent [online]. Available from: http://www.aidsinfonihgov/ContentFiles/AdultandAdolescentGLpdf. Accessed 2010 January 1.
5. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet. 2003;362(9400):2002-2011.
6. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364(9428):51-62.
7. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000;182(5):1375-1384.
8. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002;288(2):169-180.
9. Lederman MM, Miller V, Weller I, Deeks SG. A new approach for 'deep salvage' trials in advanced HIV infection. AIDS. 2007;21(12): 1503-1506.
10. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287(5453):646-650.
11. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339-354.
12. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrugresistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49(9):1441-1449.
13. Grant PM, Palmer S, Bendavid E, et al. Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. J Clin Virol. 2009;46(4):305-308.
14. Scherrer AU, von Wyl V, Fux CA, et al. Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures. J Acquir Immune Defic Syndr. 2010;53(4):464-471.
15. Statistics Denmark [online]. Available from: http://www.sdt.dk. Accessed 2010 January 1.
16. Lohse N, Hansen AB, Jensen-Fangel S, et al. Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study. Scand J Infect Dis. 2005;37(5):338-343.
17. Jensen-Fangel S, Pedersen L, Pedersen C, et al. The effect of race/ ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis. 2002;35(12):1541-1548.
18. Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sorensen HT. Cohort profile: the Danish HIV cohort study. Int J Epidemiol. 2009;38(5):1202-1206.
19. Audelin AM, Lohse N, Obel N, Gerstoft J, Jorgensen LB. The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther. 2009;14(7):995-1000.
20. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608-1618.
21. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010;24(2):223-230.
22. Cocohoba J. The SWITCHMRK studies: substitution of lopinavir/ ritonavir with raltegravir in HIV-positive individuals. Expert Rev Anti Infect Ther. 2009;7(10):1159-1163.
23. Thuret I, Chaix ML, Tamalet C, et al. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus. AIDS. 2009;23(17):2364-2366.
24. Willig JH, Aban I, Nevin CR, et al. Comparative regimen durability and discontinuation reasons among 3-class experienced patients in a US clinical cohort [poster]. EACs. 2009 Nov 11-14; Cologne, Germany.